Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Northwestern University, Yonsei University, Yonsei Cancer Hospital, Instituto de Investigación Biomédica de Málaga, Hospital Clínic de Barcelona, Hospital Universitario Virgen Macarena, Hospital Universitario de Valme, University of California, Los Angeles, Chinese University of Hong Kong, Istituti di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori Regina Elena, Stanford Medicine, Stanford University, Gilead Sciences (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), German Center for Lung Research, LungenClinic Grosshansdorf
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4400036841